Biotechnology

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

A new partnership between Japan's Ono Pharma and US biotech Mediar aims to disrupt the massive fibro-inflammatory disease market by targeting the root cell of scarring.

With a strong cash runway to 2028 and key data expected, Aclaris is advancing a multi-asset portfolio against complex immuno-inflammatory diseases.

Opal Therapeutics' organoid platform, backed by a major NSF award, bypasses failed animal models to fast-track cures for endometriosis and fibroids.

Actimed Therapeutics reclaims S-oxprenolol, a promising ALS drug. This isn't just a pipeline shuffle; it's a calculated move to dominate the future of muscle health.

Fosun International’s recent triple award win isn't just a PR victory. It’s a signal of a meticulously crafted strategy where ESG, AI, and financial resilience converge.

With a pill aimed at both heart disease and blindness, BioAge Labs is betting its future on fighting aging itself. Is this the dawn of a new era in medicine?

Facing the biotech cash crunch, Context Therapeutics shelves one drug to double down on two others, a strategic pivot that secures its future into late 2027.

With a new $345 genome and major clinical wins, PacBio pushes boundaries. But can its strategic restructuring and bold R&D overcome mounting financial losses?

Cytek Biosciences raises 2026 guidance on new tech, but rising costs and a wider net loss have investors questioning its path to sustainable profit.

GRAIL’s Galleri test shows stunning clinical results and sales growth, but staggering financial losses and a looming FDA review create a high-wire act for innovation.

Phoenix Nest secures a pivotal $3M NIH grant to manufacture a potential cure for Sanfilippo syndrome, a fatal childhood disease with no current treatment.

Soprano Eleonora Buratto lends her voice to fight 'butterfly disease,' highlighting an innovative venture philanthropy model rewriting the playbook for rare illnesses.

Acrivon's ACR-2316 shows durable responses in lung cancer, moving to the next phase. The trial's design, guided by AI, aligns with new FDA standards.

Colossal’s new fund pairs genetic engineering with grassroots conservation, offering a high-tech, high-stakes lifeline to species from ferrets to sea stars.

Expedition Therapeutics lands a huge Series B and starts a pivotal trial for a drug that could finally target the root cause of COPD for millions.

Biotech firm Kindred Companion Sciences has used CRISPR to create two beagles free of the main allergen, offering hope to millions but raising complex ethical questions.

A quiet South Korean biotech is shaking up the drug delivery landscape. Alteogen's latest deal signals a major shift as Big Pharma races to make treatments better.

Compass Pathways is racing towards a 2027 launch for its psilocybin therapy. But can it navigate the complex regulatory and commercial hurdles to deliver on its promise?

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.